 Anti-Obesity Agents
"Anti-Obesity Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.
| Descriptor ID |
D019440
|
| MeSH Number(s) |
D27.505.954.427.140
|
| Concept/Terms |
Anti-Obesity Agents- Anti-Obesity Agents
- Agents, Anti-Obesity
- Anti Obesity Agents
- Anti-Obesity Drugs
- Anti Obesity Drugs
- Drugs, Anti-Obesity
- Antiobesity Drugs
- Drugs, Antiobesity
- Antiobesity Agents
- Agents, Antiobesity
Weight-Loss Agents- Weight-Loss Agents
- Agents, Weight-Loss
- Weight Loss Agents
- Weight-Loss Drugs
- Drugs, Weight-Loss
- Weight Loss Drugs
|
Below are MeSH descriptors whose meaning is more general than "Anti-Obesity Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Obesity Agents".
This graph shows the total number of publications written about "Anti-Obesity Agents" by people in this website by year, and whether "Anti-Obesity Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 2004 | 1 | 1 | 2 | | 2006 | 0 | 1 | 1 | | 2008 | 0 | 2 | 2 | | 2009 | 1 | 2 | 3 | | 2012 | 2 | 0 | 2 | | 2013 | 2 | 2 | 4 | | 2014 | 1 | 1 | 2 | | 2015 | 2 | 0 | 2 | | 2016 | 3 | 0 | 3 | | 2018 | 2 | 2 | 4 | | 2019 | 3 | 0 | 3 | | 2021 | 1 | 1 | 2 | | 2023 | 4 | 0 | 4 | | 2024 | 2 | 3 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Anti-Obesity Agents" by people in Profiles.
-
Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025 Mar 06; 392(10):958-971.
-
Armstrong SC, Eneli I, Osganian SK, Wagner BE, Waldrop SW, Kelly AS. Pediatric Obesity Pharmacotherapy: State of the Science, Research Gaps, and Opportunities. Pediatrics. 2024 Nov 01; 154(5).
-
Vidmar AP, Batt CE, Moore JM. Assessment and medical management of weight regain after adolescent metabolic and bariatric surgery: a narrative review. Surg Obes Relat Dis. 2025 Jan; 21(1):24-32.
-
Gilden AH, Catenacci VA, Taormina JM. Obesity. Ann Intern Med. 2024 05; 177(5):ITC65-ITC80.
-
Cook TM, Sandoval D. Dual-action obesity drug rewires brain circuits for appetite. Nature. 2024 May; 629(8014):1011-1012.
-
Bernstein EY, Moreno JO, Edelman EJ. Expanding the Use of Medications for Alcohol Use Disorder: Lessons from the Proliferation of Anti-obesity Medications. J Gen Intern Med. 2024 May; 39(7):1233-1235.
-
Wadden TA, Chao AM, Moore M, Tronieri JS, Gilden A, Amaro A, Leonard S, Jakicic JM. The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. Curr Obes Rep. 2023 Dec; 12(4):453-473.
-
Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity Management in Adults: A Review. JAMA. 2023 11 28; 330(20):2000-2015.
-
Perreault L, Suresh K, Rodriguez C, Dickinson LM, Willems E, Smith PC, Williams J, Gritz RM, Holtrop JS. Baseline Characteristics of PATHWEIGH: A Stepped-Wedge Cluster Randomized Study for Weight Management in Primary Care. Ann Fam Med. 2023 May-Jun; 21(3):249-255.
-
Kheniser K, Saxon DR, Kashyap SR. Long-Term Weight Loss Strategies for Obesity. J Clin Endocrinol Metab. 2021 06 16; 106(7):1854-1866.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|